Aspira Women's Health Inc. (AWH)
USD 0.1
(0.93%)
USD 0.1
(0.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -18.85 Million USD | 42.46% |
| 2022 | -32.76 Million USD | -0.52% |
| 2021 | -32.59 Million USD | -81.27% |
| 2020 | -17.98 Million USD | -17.69% |
| 2019 | -15.27 Million USD | -34.81% |
| 2018 | -11.33 Million USD | -8.54% |
| 2017 | -10.44 Million USD | 30.18% |
| 2016 | -14.95 Million USD | 22.31% |
| 2015 | -19.24 Million USD | -0.2% |
| 2014 | -19.21 Million USD | -116.76% |
| 2013 | -8.86 Million USD | 5.85% |
| 2012 | -9.41 Million USD | 46.64% |
| 2011 | -17.64 Million USD | -20.81% |
| 2010 | -14.6 Million USD | -172.27% |
| 2009 | -5.36 Million USD | 63.06% |
| 2008 | -14.51 Million USD | 26.01% |
| 2007 | -19.62 Million USD | -3.83% |
| 2006 | -18.89 Million USD | 45.24% |
| 2005 | -34.5 Million USD | 0.48% |
| 2004 | -34.67 Million USD | 3.36% |
| 2003 | -35.88 Million USD | -18.14% |
| 2002 | -30.37 Million USD | -3.19% |
| 2001 | -29.43 Million USD | -29.88% |
| 2000 | -22.66 Million USD | -183.62% |
| 1999 | -7.99 Million USD | -1.02% |
| 1998 | -7.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.39 Million USD | 6.73% |
| 2024 Q1 | -4.71 Million USD | -13.91% |
| 2023 Q3 | -4.11 Million USD | 4.74% |
| 2023 Q1 | -5.76 Million USD | -3.0% |
| 2023 FY | -18.85 Million USD | 42.46% |
| 2023 Q2 | -4.32 Million USD | 25.1% |
| 2023 Q4 | -4.13 Million USD | -0.46% |
| 2022 Q3 | -9.69 Million USD | -17.97% |
| 2022 Q2 | -8.22 Million USD | 11.11% |
| 2022 Q1 | -9.24 Million USD | -3.36% |
| 2022 FY | -32.76 Million USD | -0.52% |
| 2022 Q4 | -5.6 Million USD | 42.24% |
| 2021 Q3 | -9.69 Million USD | -20.06% |
| 2021 Q1 | -5.88 Million USD | 3.1% |
| 2021 Q4 | -8.94 Million USD | 7.69% |
| 2021 Q2 | -8.07 Million USD | -37.14% |
| 2021 FY | -32.59 Million USD | -81.27% |
| 2020 Q3 | -4.28 Million USD | -11.89% |
| 2020 Q2 | -3.82 Million USD | -0.68% |
| 2020 FY | -17.98 Million USD | -17.69% |
| 2020 Q1 | -3.8 Million USD | -11.63% |
| 2020 Q4 | -6.07 Million USD | -41.88% |
| 2019 Q3 | -3.85 Million USD | 10.57% |
| 2019 FY | -15.27 Million USD | -34.81% |
| 2019 Q2 | -4.3 Million USD | -15.76% |
| 2019 Q1 | -3.71 Million USD | -31.69% |
| 2019 Q4 | -3.4 Million USD | 11.58% |
| 2018 Q3 | -2.64 Million USD | 12.8% |
| 2018 Q4 | -2.82 Million USD | -6.85% |
| 2018 FY | -11.33 Million USD | -8.54% |
| 2018 Q1 | -2.83 Million USD | 3.57% |
| 2018 Q2 | -3.03 Million USD | -6.91% |
| 2017 Q3 | -2.49 Million USD | -6.52% |
| 2017 Q2 | -2.34 Million USD | 11.67% |
| 2017 Q1 | -2.65 Million USD | 6.21% |
| 2017 FY | -10.44 Million USD | 30.18% |
| 2017 Q4 | -2.94 Million USD | -17.65% |
| 2016 Q3 | -3.46 Million USD | 7.87% |
| 2016 Q1 | -4.89 Million USD | 2.0% |
| 2016 Q2 | -3.76 Million USD | 23.18% |
| 2016 Q4 | -2.83 Million USD | 18.27% |
| 2016 FY | -14.95 Million USD | 22.31% |
| 2015 FY | -19.24 Million USD | -0.2% |
| 2015 Q4 | -4.99 Million USD | 2.86% |
| 2015 Q3 | -5.14 Million USD | -6.08% |
| 2015 Q2 | -4.84 Million USD | -13.75% |
| 2015 Q1 | -4.26 Million USD | -4.74% |
| 2014 Q2 | -5.55 Million USD | -39.12% |
| 2014 Q3 | -5.58 Million USD | -0.56% |
| 2014 FY | -19.21 Million USD | -116.76% |
| 2014 Q4 | -4.06 Million USD | 27.2% |
| 2014 Q1 | -3.99 Million USD | -118.9% |
| 2013 Q1 | -2.6 Million USD | -103.12% |
| 2013 Q3 | -2.31 Million USD | -9.34% |
| 2013 Q2 | -2.11 Million USD | 18.56% |
| 2013 Q4 | -1.82 Million USD | 21.23% |
| 2013 FY | -8.86 Million USD | 5.85% |
| 2012 Q4 | -1.28 Million USD | 44.26% |
| 2012 Q2 | -3.67 Million USD | -69.64% |
| 2012 FY | -9.41 Million USD | 46.64% |
| 2012 Q1 | -2.16 Million USD | 29.51% |
| 2012 Q3 | -2.29 Million USD | 37.4% |
| 2011 Q4 | -3.07 Million USD | 32.18% |
| 2011 Q1 | -4.44 Million USD | -4.51% |
| 2011 Q3 | -4.52 Million USD | 19.12% |
| 2011 Q2 | -5.59 Million USD | -25.86% |
| 2011 FY | -17.64 Million USD | -20.81% |
| 2010 Q4 | -4.25 Million USD | -18.19% |
| 2010 Q3 | -3.6 Million USD | 3.82% |
| 2010 Q2 | -3.74 Million USD | -24.6% |
| 2010 Q1 | -3 Million USD | -100.27% |
| 2010 FY | -14.6 Million USD | -172.27% |
| 2009 Q3 | -692 Thousand USD | 33.65% |
| 2009 FY | -5.36 Million USD | 63.06% |
| 2009 Q4 | -1.5 Million USD | -116.76% |
| 2009 Q2 | -1.04 Million USD | 50.99% |
| 2009 Q1 | -2.12 Million USD | 39.36% |
| 2008 Q1 | -4.56 Million USD | -58.42% |
| 2008 FY | -14.51 Million USD | 26.01% |
| 2008 Q2 | -3.4 Million USD | 25.31% |
| 2008 Q3 | -3.03 Million USD | 10.97% |
| 2008 Q4 | -3.5 Million USD | -15.62% |
| 2007 Q2 | -6.29 Million USD | -11.22% |
| 2007 Q1 | -5.65 Million USD | -6716.87% |
| 2007 FY | -19.62 Million USD | -3.83% |
| 2007 Q4 | -2.88 Million USD | 39.83% |
| 2007 Q3 | -4.78 Million USD | 23.92% |
| 2006 Q2 | -7.22 Million USD | -41.24% |
| 2006 Q1 | -5.11 Million USD | 48.48% |
| 2006 Q3 | -6.47 Million USD | 10.33% |
| 2006 Q4 | -83 Thousand USD | 98.72% |
| 2006 FY | -18.89 Million USD | 45.24% |
| 2005 FY | -34.5 Million USD | 0.48% |
| 2005 Q1 | -8.77 Million USD | -35.63% |
| 2005 Q3 | -7 Million USD | 17.05% |
| 2005 Q4 | -9.92 Million USD | -41.63% |
| 2005 Q2 | -8.45 Million USD | 3.66% |
| 2004 Q2 | -12.75 Million USD | -90.44% |
| 2004 Q1 | -6.69 Million USD | 3.05% |
| 2004 Q3 | -8.75 Million USD | 31.31% |
| 2004 FY | -34.67 Million USD | 3.36% |
| 2004 Q4 | -6.46 Million USD | 26.17% |
| 2003 Q2 | -15.25 Million USD | -67.19% |
| 2003 Q4 | -6.9 Million USD | -50.58% |
| 2003 Q1 | -9.12 Million USD | -31.06% |
| 2003 Q3 | -4.58 Million USD | 69.94% |
| 2003 FY | -35.88 Million USD | -18.14% |
| 2002 Q3 | -8.25 Million USD | -8.8% |
| 2002 Q4 | -6.96 Million USD | 15.65% |
| 2002 FY | -30.37 Million USD | -3.19% |
| 2002 Q1 | -7.56 Million USD | 9.73% |
| 2002 Q2 | -7.58 Million USD | -0.34% |
| 2001 Q1 | -7.4 Million USD | -10.74% |
| 2001 FY | -29.43 Million USD | -29.88% |
| 2001 Q4 | -8.37 Million USD | -24.68% |
| 2001 Q3 | -6.71 Million USD | 3.03% |
| 2001 Q2 | -6.92 Million USD | 6.44% |
| 2000 Q1 | 1.82 Million USD | 0.0% |
| 2000 Q2 | 1.82 Million USD | 0.05% |
| 2000 Q4 | -6.68 Million USD | -5.91% |
| 2000 Q3 | -6.31 Million USD | -446.79% |
| 2000 FY | -22.66 Million USD | -183.62% |
| 1999 FY | -7.99 Million USD | -1.02% |
| 1998 FY | -7.9 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| bioAffinity Technologies, Inc. | -7.97 Million USD | -136.441% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -83.329% |
| Standard BioTools Inc. | -76.6 Million USD | 75.389% |
| Inotiv, Inc. | -81.46 Million USD | 76.857% |
| Prenetics Global Limited | -52.51 Million USD | 64.101% |
| Neuronetics, Inc. | -30.55 Million USD | 38.299% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -333.778% |
| Castle Biosciences, Inc. | -67.97 Million USD | 72.267% |
| Psychemedics Corporation | -2.92 Million USD | -545.395% |
| RadNet, Inc. | 98.69 Million USD | 119.101% |
| Exact Sciences Corporation | -215.01 Million USD | 91.232% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 101.718% |
| iSpecimen Inc. | -11.16 Million USD | -68.783% |
| OpGen, Inc. | -15.68 Million USD | -20.165% |
| Exagen Inc. | -22.83 Million USD | 17.45% |
| Bionano Genomics, Inc. | -215.24 Million USD | 91.242% |
| CareDx, Inc | -101.9 Million USD | 81.5% |
| Check-Cap Ltd. | -19.28 Million USD | 2.255% |
| Twist Bioscience Corporation | -220.83 Million USD | 91.463% |
| Guardant Health, Inc. | -564.72 Million USD | 96.662% |
| Biodesix, Inc. | -41.34 Million USD | 54.4% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -626.869% |
| Precipio, Inc. | -7.62 Million USD | -147.402% |
| Natera, Inc. | -446.24 Million USD | 95.775% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 74.067% |
| Sera Prognostics, Inc. | -39.82 Million USD | 52.658% |
| 23andMe Holding Co. | -321.35 Million USD | 94.134% |
| OPKO Health, Inc. | -157.02 Million USD | 87.994% |
| Personalis, Inc. | -109.93 Million USD | 82.852% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 80.636% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -72.113% |
| T2 Biosystems, Inc. | -49.66 Million USD | 62.041% |
| Neogen Corporation | 58.66 Million USD | 132.136% |
| Myriad Genetics, Inc. | -123.7 Million USD | 84.76% |
| ICON Public Limited Company | 956.15 Million USD | 101.972% |
| NeoGenomics, Inc. | -107.73 Million USD | 82.502% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -333.778% |
| MDxHealth SA | -27.32 Million USD | 31.013% |
| Prenetics Global Limited | -52.51 Million USD | 64.101% |
| Illumina, Inc. | -1.06 Billion USD | 98.236% |
| DarioHealth Corp. | -56.18 Million USD | 66.449% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -79.189% |
| Medpace Holdings, Inc. | 336.82 Million USD | 105.597% |
| Mainz Biomed B.V. | -26.64 Million USD | 29.247% |
| Trinity Biotech plc | -27.04 Million USD | 30.294% |
| Sotera Health Company | 276.69 Million USD | 106.813% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -136.441% |